Effect of olmesartan on oxidative stress in hypertensive patients. Mechanistic support to clinical trials derived evidence

Blood Pressure

Volumn 20, Issue 6, 2011, Pages 376-382

  Calò, Lorenzo A ^a   Maso, Lucia Dal ^a   Caielli, Paola ^a   Pagnin, Elisa ^a   Fusaro, Maria ^b   Davis, Paul A ^c   Pessina, Achille C ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b CNR   (Italy)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

ERK; HO 1; hypertension; olmesartan; oxidative stress; p22 phox

Indexed keywords

HEME OXYGENASE 1; MITOGEN ACTIVATED PROTEIN KINASE 1; OLMESARTAN; OXIDIZED LOW DENSITY LIPOPROTEIN; PROTEIN P22;

ADULT; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL (TOPIC); ENZYME LINKED IMMUNOSORBENT ASSAY; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; OXIDATIVE STRESS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

ADULT; ANTIHYPERTENSIVE AGENTS; ANTIOXIDANTS; BLOOD PRESSURE; BLOTTING, WESTERN; CLINICAL TRIALS AS TOPIC; DRUG ADMINISTRATION SCHEDULE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEME OXYGENASE-1; HUMANS; HYPERTENSION; IMIDAZOLES; ITALY; LEUKOCYTES, MONONUCLEAR; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NADPH OXIDASE; OXIDATIVE STRESS; PHOSPHORYLATION; TETRAZOLES;

EID: 81255165820     PISSN: 08037051     EISSN: 16511999     Source Type: Journal    
DOI: 10.3109/08037051.2011.575570     Document Type: Article

References (55)

1. Luft FC. Mechanisms and cardiovascular damage in hypertension. Hypertension. 2001;37 (part 2): 594-598.
2. Touyz RM. Reactive oxygen species, vascular oxidative stress, and redox signaling in hypertension: what is the clinical signifi cance? Hypertension. 2004;44:248-252.
3. Harrison D, Griendling KK, Landmesser U, Hornig B, Drexler H. Role of oxidative stress in atherosclerosis. Am J Cardiol. 2003;91(3A):7A - 11A.
4. Moncada S, Palmer RMJ, Higgs EA. Nitric oxide: physiology, pathophysiology and pharmacology. Pharmacol Rev. 1991;43: 109-142.
5. Dubey RK, Jackson EK, Lüsher TF. Nitric oxide inhibits angiotensin II-induced migration of rat aortic smooth muscle cell. Role of cyclic nucleotides and angiotensin 1 receptors. J Clin Invest. 1995;96:141-149.
6. Kadowaki D, Anraku M, Tasaki Y, Kitamura K, Wakamatsu S, Tomita K, et al. Effect of olmesartan on oxidative stress in hemodialysis patients. Hypertens Res. 2007;30:395-402.
7. Fliser D, Wagner KK, Loos A, Tsikas D, Haller H. Chronic angiotensin II receptor blockade reduces (intra)renal vascular resistance in patients with type 2 diabetes. J Am Soc Nephrol. 2005;16:1135-1140.
8. Oyama N, Yagita Y, Sasaki T, Omura-Matsuoka E, Terasaki Y, Sugiyama Y, et al. An angiotensin II type 1 receptor blocker can preserve endothelial function and attenuate brain ischemic damage in spontaneously hypertensive rats. J Neurosci Res. 2010;88:2889-2898.
9. Kanematsu Y, Tsuchiya K, Ohnishi H, Motobayashi Y, Izawa Y, Ishihara M, et al. Effects of angiotensin II type 1 receptor blockade on the systemic blood nitric oxide dynamics in N -omega-nitro- L -arginine methyl ester-treated rats. Hypertens Res. 2006;29:369-374.
10. Fliser D, Buchholz K, Haller H. Antiinfl ammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinfl ammation. Circulation. 2004;110: 1103-1107.
11. Smith RD, Yokoyama H, Averill DB, Cooke L, Brosnihan KB, Schiffrin EL, et al. The protective effects of angiotensin II blockade with olmesartan medoxomil on resistance vessel remodeling (the VIOS study): Rationale and baseline characteristics. Am J Cardiovasc Drugs. 2006;6:335-342.
12. Stumpe KO, Agabiti-Rosei E, Zielinski T, Schremmer D, Scholze J, Laeis P, et al. Carotid intima-media thickness and plaque volume changes following 2-year angiotensin IIreceptor blockade. The Multicentre Olmesartan atherosclerosis Regression Evaluation (MORE) study. Ther Adv Cardiovasc Dis. 2007;1:97-106.
13. Hirohata A, Yamamoto K, Miyoshi T, Hatanaka K, Hirohata S, Yamawaki H, et al. Impact of olmesartan on progression of coronary atherosclerosis: A serial volumetric intravascular ultrasound analysis from the OLIVUS (Impact of olmesartan on progression of coronary atherosclerosis: Evaluation by intravascular ultrasound) trial. J Am Coll Cardiol. 2010;55: 976-982.
14. Griendling KK, Soresen D, Ushio-Fukai M. NAD(P)H oxidase. Role in cardiovascular biology and disease. Circ Res. 2000;86:494-501.
15. Datla SR, Griendling KK. Reactive oxygen species, NADPH oxidases and hypertension. Hypertension. 2010;56:325-330.
16. Dhalla NS, Temsha RM, Netticadan T. Role of oxidative stress in cardiovascular diseases. J Hypertens. 2000;18:655-673.
17. Maines MD. The heme oxygenase system: A regulator of second messenger gases. Annu Rev Pharmacol Toxicol. 1997; 37:517-554.
18. Stocker R, Perrella MA. Heme oxygenase-1. A novel drug target for atherosclerotic diseases? Circulation; 2006;114: 2178-2189.
19. McCubrey JA, Lahair MM, Franklin RA. Reactive oxygen species-induced activation of the MAP kinase signaling pathways. Antioxid Redox Signal. 2006;8:1775-1789.
20. Calò LA, Naso A, Carraro G, Wratten ML, Pagnin E, Bertipaglia L, et al. Effect of haemodiafi ltration with online regeneration of ultrafi ltrate on oxidative stress in dialysis patients. Nephrol Dial Transplant. 2007;22:1413-1419.
21. Calò LA, Davis PA, Pagnin E, Bertipaglia L, Naso A, Piccoli A, et al. Carnitine-mediated improved response to erythropoietininvolves indction of haem oxygenase-1: Studies in humans and in an animal model. Nephrol Dial Transplant. 2008;23: 890-895.
22. Calò LA, Naso A, D'Angelo A, Pagnin E, Zanardo M, Puato M, et al. Molecular biology based assessment of Vitamin E-coated dialyzer effects on oxidative stress, infl ammation and vascular remodeling. Artif Organs. 2011;35:E33-E339.
23. Calò LA, Schiavo S, Davis PA, Pagnin E, Mormino P, D'Angelo A, et al. Angiotensin II signaling via type 2 receptors in a human model of vascular hyporeactivity: Implications for hypertension. J Hypertens. 2010;28:111-118.
24. Avogaro A, Pagnin E, Calo L. Monocyte NADPH oxidase subunit p22(phox) and inducible hemeoxygenase-1 gene expressions are increased in type II diabetic patients: Relationship with oxidative stress. J Clin Endocrinol Metab. 2003;88:1753-1759.
25. Moser M and Frishman W. Results of therapy with carvedilol, a b-blocker vasodilator with antioxidant properties, in hypertensive patients. Am J Hypertens. 1998;11:15S - 22S.
26. Calò L, Giacon B, Davis PA, Pagnin E, Piccin A, Riegler P, et al. Oxidative stress and TGF β?in kidney-transplanted patients with cyclosporin-induced hypertension. Effect of carvedilol and nifedipine. Clin Nephrol. 2002;56:103-110.
27. Mak IT, Zhang J, Weglicki WB. Protective effects of dihydropyridine Ca-blockers against endothelial cell oxidative injury due to combined nitric oxide and superoxide. Pharmacol Res. 2002;45:27-33.
28. Calò LA, Zaghetto F, Pagnin E, Davis PA, Semplicini A, Pessina AC. Effect of manidipine on gene expression and protein level of oxidative stress-related proteins: p22phox and HO-1: Relevance for antihypertensive and anti-remodeling effects. J Cardiovasc Pharmacol. 2004;43:531-538.
29. Calò LA, Bertipaglia L, Pagnin E, Davis PA, Sartori M, Semplicini A, et al. Effect of doxazosin on oxidative stress related proteins in essential hypertensive patients. Clin Exp Hypertens. 2006;28:181-188.
30. Calò LA, Davis PA, Giacon B, Pagnin E, Sartori M, Riegler P, et al. Oxidative stress in kidney transplant patients with calcineurin inhibitor-induced hypertension: Effect of ramipril. J Cardiovasc Pharmacol. 2002;40:625-631.
31. Izuhara Y, Nangaku M, Inagi R, Tominaga N, Aizawa T, Kurokawa K, et al. Renoprotective properties of angiotensin receptor blockers beyond blood pressure lowering. J Am Soc Nephrol. 2005;16:3631-3641.
32. Hilgers KF. Monocytes/macrophages in hypertension. J Hypertens. 2002;20:593-596.
33. Y asunari K, Maeda K, Nakamura M, and Yoshikawa J. Oxidative stress in leukocytes is a possible link between blood pressure, blood glucose, and C-reacting protein. Hypertension. 2002;39:777-780.
34. Immenschuh S, Ramadori G. Gene regulation of heme oxygenase-1 as a therapeutic target. Biochem Pharmacol. 2000;60:1121-1128.
35. Kim S, Iwao H. Molecular and cellular mechanisms of Ang II-mediated cardiovascular and renal diseases. Pharmacol Rev. 2000;52:11-34.
36. Mehta PK and Griendling KK. Angiotensin II cell signaling: Physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol. 2007;292:82-97.
37. Touyz RM. Role of angiotensin II in regulating vascular structural and functional changes in hypertension. Curr Hypertens Rep. 2003;5:155-164.
38. Dzau VJ and Lopez-Ilasaca M. Searching for transcriptional regulators of Ang II-induced vascular pathology. J Clin Invest. 2005;115:2319-2322.
39. Zhan Y, Brown C, Maynard E, Anshelevich A, Ni W, Ho IC, et al. Ets-1 is a critical regulator of Ang II-mediated vascular infl ammation and remodeling. J Clin Invest. 2005;115: 2508-2516.
40. Hansen JL, Servant G, Baranski TJ, Fujita T, Iiri T, Sheikh SP. Functional Reconstitution of the angiotensin II type 2 receptor and Gi activation. Circ Res. 2000;87:753-759.
41. Savoia C, Tabet F, Yao G, Schiffrin E, Touyz R. Negative regulation of Rho/Rho kinase by angiotensin II type 2 receptor in vascular smooth muscle cells: Role in angiotensin II-induced vasodilation in stroke-prone spontaneously hypertensive rats. J Hypertens. 2005;23:1037-1045.
42. Naesens M, Steels P, Verberckmoes R, Vanrenterghem Y, Kuypers D. Bartter ' s and Gitelman ' s Syndromes: From gene to clinic. Nephron Physiol. 2004;96:65-78.
43. Calò LA. Vascular tone control in humans: The utility of studies in Bartter ' s/Gitelman ' s syndromes. Kidney Int. 2006; 69:963-966.
44. Calò LA, Pagnin E, Davis PA, Sartori M, Ceolotto G, Pessina AC, et al. Increased expression of regulator of G protein signaling-2 (RGS-2) in Bartter ' s/Gitelman ' s sydrome. A role in the control of vascular tone and implication for hypertension. J Clin Endocrinol Metabol. 2004;89:4153-4157.
45. Calò LA, Pagnin E, Ceolotto G, Davis PA, Schiavo S, Papparella I, et al. Silencing regulator of G protein signaling-2 (RGS-2) increases angiotensin II signaling: Insights into hypertension from fi ndings in Bartter ' s/Gitelman ' s syndromes. J Hypertens. 2008;26:938-945.
46. Calò LA, Pessina AC. RhoA/Rho-kinase pathway: Much more than just a modulation of vascular tone. Evidence from studies in humans. J Hypertens. 2007;25:259-264.
47. Davis PA, Pagnin E, Semplicini A, Avogaro A, Calò LA. Insulin signaling, glucose metabolism and the angiotensin II signaling system. Studies in Bartter ' s/Gitelman ' s syndromes. Diabetes Care. 2006;29:469-471.
48. Calò LA, Davis PA, Palatini P, Semplicini A, Pessina AC. Urinary albumin excretion, endothelial dysfunction and cardiovascular risk: Study in Bartter ' s/Gitelman ' s syndromes and relevance for hypertension. J Hum Hypertens. 2007;21: 904-906.
49. Calò L, Sartore G, Bassi A, Basso C, Bertocco S, Marin R, et al. Reduced susceptibility of low density lipoprotein to oxidation in patients with overproduction of nitric oxide (Bartter ' s and Gitelman ' s syndrome). J Hypertens. 1998;16:1001-1008.
50. Calò LA, Pagnin E, Davis PA, Sartori M, Semplicini A. Oxidative stress related factors in Bartter ' s and Gitelman ' s syndromes: Relevance for angiotensin II signalling. Nephrol Dial Transplant. 2003;18:1518-1525.
51. Calò L, Davis PA, Milani M, Cantaro S, Antonello A, Favaro S, et al. Increased endothelial nitric oxide synthase mRNA level in Bartter ' s and Gitelman ' s syndrome. Relationship to vascular reactivity. Clin Nephrol. 1999;51:12-17.
52. Caló L, D'Angelo A, Cantaro S, Bordin MC, Favaro S, Antonello A, et al. Increased urinary NO2-/NO2- and cyclic GMP levels in patients with Bartter ' s syndrome: Relationship to vascular reactivity. Am J Kidney Dis. 1996;27:874-879.
53. Calò LA, Puato M, Schiavo S, Zanardo M, Tirrito C, Pagnin E, et al. Absence of vascular remodelling in a high angiotensin-II state (Bartter ' s and Gitelman ' s syndromes): Implications for angiotensin II signalling pathways. Nephrol Dial Transplant. 2008;23:2804-2809.
54. Calò LA, Montisci R, Scognamiglio R, Davis PA, Pagnin E, Schiavo S, et al. High angiotensin II state without cardiac remodeling (Bartter ' s and Gitelman ' s syndromes). Are angiotensin II type 2 receptors involved? J Endocrinol Invest. 2009;32:832-836.
55. Siragy HM. Evidence for benefi ts of angiotensin receptor blockade beyond blood pressure control. Curr Hypertens Rep. 2008;10:261-267.